Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. PLRX has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
PLRX stock price ended at $1.38 on Friday, after rising0.73%
The Pliant Therapeutics Inc stock price increased by 0.73% on the last trading day (16 May 2025), rising from 1.37 to 1.38. Throughout the last trading session, the stock experienced a fluctuation of 8.33% , ranging from a day low of $1.32 to a day high of 1.43. The price has declined in 5 of the last 10 days, resulting in a total change of -18.34% during this period. On the last day, trading volume increase by 781.52K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 1.20M shares were traded, amounting to approximately 1.65M.
PLRX Technical Signals
PLRX(Pliant Therapeutics Inc Corp) has 4 buy signals and 3 sell signals now. The current trend is downtrend starting from 2025-05-12. The total price change during this trend is -6.12%. Recently, the price has increased significantly with an increase in volume, indicating a strong bullish signal. The average turnover of PLRX over the last 5 trading days is 1.15M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
PLRX Moving Average Analysis
Pliant Therapeutics Inc's overall moving average trend leans more bearish as of Monday, May 19, 2025, with 4 negative signals and 0 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $1.72702, and $1.876. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $1.24498, and $1.096. A break-down below any of these levels will issue sell signals.
PLRX Short Selling Analysis
The short sale ratio of Pliant Therapeutics Inc(PLRX) as of 12 May 2025 is 22.74%, dropping from last trading day. With decreasing price from 1.41 to 1.47. The short sell activity indicate that short sellers may be experiencing short cover.
Technical Signal
Technical Signals Summary
Neutral
Sell
3
Buy
4
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
4 Bullish Signals
4 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 < 20
11.731
Bullish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 < -100
-115.184
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
5.532
Bullish
Williams %R (14 days)
WILLR_14 < -80
-85
Bullish
3 Bearish Signals
3 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 < 0
-0.0294
Bearish
Momentum (10 days)
MOM_10 < 0
-0.31
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.0909
Bearish
PLRX Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Pliant Therapeutics Inc(PLRX), our algorithm predicts PLRX's 1-month price at $1.21, with an -12%downwardshift. Using a similarity score up to 93.99%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Pliant Therapeutics Inc (PLRX.O) stock, as of Sunday, May 18, 2025 , forecasts a -12% change over the next month, based on its high correlation with CMCM.N stock patterns. The similarity between their price movements over the analyzed periods is 93.99%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
PLRX
Future prediction
Up: -12%
CMCM
Down: -12%Similarity: 93.99%
Name
Similarity
Up/Down
CMCM.N
93.99%
-12.00%
XPL.A
93.61%
+6.51%
TTC.N
93.48%
+8.20%
TPL.N
93.46%
+20.27%
BLBX.O
93.46%
+6.38%
SB.N
93.44%
+18.28%
OMAB.O
93.28%
-28.24%
ICLR.O
93.21%
-4.66%
NOMD.N
93.14%
-11.24%
MUSA.N
93.11%
-0.31%
PLRX Seasonality Analysis
Based on PLRX's historical stock price data across all years, the probability of a positive return in May is20.00%, suggesting it maynotbe an ideal month to invest in PLRX. In contrast,Julyoffers the highest probability of positive returns at50.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Pliant Therapeutics Inc (PLRX.O) stock in July has the highest probability of a positive return (50.00%), while February has the lowest probability (20.00%).
Performance Seasonality
The chart shows Pliant Therapeutics Inc. (PLRX)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
Should I buy Pliant Therapeutics Inc (PLRX.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. PLRX has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Pliant Therapeutics Inc (PLRX.O) stock in a year?
The radar chart shows that buying Pliant Therapeutics Inc (PLRX.O) stock in July has the highest probability of a positive return (50.00%), while February has the lowest probability (20.00%).
How has Pliant Therapeutics Inc. (PLRX)'s stock price performed over the past three years?
PLRX's stock price fell by -4.68% in 2023,decreased by -26.67% in 2024, and went down by 89.61% in 2025.
Is PLRX a buy based on overall technical signals summary?
PLRX has 4 buy signals and 3 sell signals now. Overall the technical rating for PLRX is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of PLRX.
What is the trend of Pliant Therapeutics Inc (PLRX)'s moving average?
Pliant Therapeutics Inc's overall moving average trend leans more bearish as of May 19 2025, with 4 negative signals and 0 positive signal.
What is price prediction for PLRX stock next month?
The price prediction chart for Pliant Therapeutics Inc (PLRX.O) stock, as of May 18 2025, forecasts a -12% change over the next month, based on its high correlation with CMCM stock patterns. The similarity between their price movements over the analyzed periods is 93.99%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for PLRX Stock?
PLRX stock is predicted to trade between $1.20 and $2.00 in 2025, driven by clinical trial developments and market sentiment. The stock may decline to $1.20 if the BEACON-IPF trial discontinuation weighs heavily on investor confidence. Conversely, positive interim results from PLN-101095 could push it to $2.00.
What is price prediction 2030 for PLRX Stock?
Pliant Therapeutics (PLRX) stock is predicted to reach **$5.00 by 2030** driven by potential FDA approvals and successful late-stage trials. The stock could drop to **$0.50** if clinical trials fail or adverse events persist. Current oversold conditions and pipeline potential suggest a **base case of $2.50 by 2030**.